Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Free cash flow
Gilead Sciences, Inc.'s free cash flow for fiscal 2025 was $9.5B, down 8.24% from $10.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $12.9B. Over the past ten years it has ranged from $7.4B (fiscal 2023) to $20.5B (fiscal 2015); the current reading is higher than 55% of that period. Gilead Sciences, Inc. ranks 7th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $9.5B | (8.24%) |
| FY2024 | $10.3B | 38.86% |
| FY2023 | $7.4B | (11.06%) |
| FY2022 | $8.3B | (22.78%) |
| FY2021 | $10.8B | 43.72% |
| FY2020 | $7.5B | (9.63%) |
| FY2019 | $8.3B | 11.28% |
| FY2018 | $7.5B | (33.89%) |
| FY2017 | $11.3B | (30.62%) |
| FY2016 | $16.3B | (20.50%) |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $3.4B | 41.45% |
| Mar 2026 | $2.4B | (22.26%) |
| Dec 2025 | $3.1B | (21.18%) |
| Sep 2025 | $4.0B | 450.14% |
| 42 more quarters | Free account |
Against its own ten years
Low $7.4B
High $20.5B
Ten-year median
$9.5B
Current reading's percentile
55
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| NVS Novartis AG compare | $15.2B |
| SNY Sanofi compare | $14.5B |
| GILD Gilead Sciences, Inc. | $12.9B |
| BMY Bristol Myers Squibb Company compare | $11.4B |
| PFE Pfizer Inc. compare | $11.0B |
| AMGN Amgen Inc. compare | $10.2B |
| GSK GSK PLC Sponsored ADR compare | $7.6B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GILD
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement